Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$259.47M-12.7%-$230.32M-7.8%-$213.7M-19.3%-$179.12M-21.2%-$147.83M-21.9%
$3.08M+17.9%$2.62M+17.4%$2.23M+21.5%$1.84M+27.9%$1.44M+3.6%
$23.96M+85.8%$12.9M+14.7%$11.24M+19.9%$9.38M+18.8%$7.9M+8.4%
-$224.15M-14.4%-$196.01M-5.6%-$185.69M-11.6%-$166.42M-19.1%-$139.78M-19.9%
$343K-34.0%
$85.57M
$73.02M
$103.52M-29.1%$146M+98.0%$73.75M+0.4%$73.46M0.0%$73.46M+43.2%
-$24.92M
-$224.15M-14.3%-$196.04M-5.5%-$185.9M-11.5%-$166.76M-19.0%-$140.12M-19.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does MoonLake Immunotherapeutics generate?
MoonLake Immunotherapeutics (MLTX) generated -$224.2M in operating cash flow over the trailing twelve months.
What is MoonLake Immunotherapeutics's free cash flow?
After $343.0K of capital expenditures, MoonLake Immunotherapeutics's free cash flow was -$224.2M over the trailing twelve months, down 60.0% year over year.
Where does MoonLake Immunotherapeutics's cash flow data come from?
Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.